Femtobiomed Co., Ltd. (CEOs Lee Sang-hyun and Choi Joo-hyun) will participate in ‘BIO KOREA 5 (Bio Korea 10)’, which will be held at COEX in Seoul for three days from Wednesday, May 12th to Friday, May 3th, and provide electroporation. Showcasing technology and devices.
FEMTOBIOMED is a leading company in the core process of cell therapy production and was first established in July 2011 under the name of FEMTOFAB. The company changed its name to its current name in 7 and is developing and producing electroporation technology and devices called ‘CellShot’. The excellence of technology and products has been certified by national organizations, including NET certification (new technology certification) at the end of 2017 and confirmation of advanced industrial technology and products hosted by the Ministry of Trade, Industry and Energy in early 2022, and global cell therapy production starting this year when full-scale commercialization is underway. Officials emphasized that preparations to lead the ‘Paradigm Shift’ of the fair market have been completed.
CellShot®, which will be introduced at this exhibition, is a non-viral, mediator-free cell transformation platform for developing and producing various new cell therapy drugs. CellShot®’s unique cell-material real-time separation and transfer technology automates the pretreatment process (cell washing and medium replacement) required for cell therapy production, thereby maximizing cell viability and overall process yield, thereby securing economic feasibility.
Femtobiomed’s proprietary CellShot technology is a product developed directly by our research team to realize high cell therapy productivity and efficiency. In addition, efforts were made to create a user-friendly operation environment, and CellShot DB was developed for data management and control. It was emphasized that this provides a user-friendly environment to users by linking with self-developed embedded SW installed on the equipment. done. The company explains that since everything from HW to SW was developed directly and was created with a focus on user needs, not only the device performance but also the operation method is intuitive.
With technology development completed at the end of 2022, Femtobiomed is conducting full-scale sales and sales activities starting this year. Accordingly, in January of this year, CellShot, an electroporation device, was successfully launched in a laboratory within an American university, and cooperation is being encouraged with domestic and foreign cell and gene therapy venture companies. In April, a supply contract worth 1 million won was signed with a domestic new drug development company, signaling the start of full-scale commercialization.
A Femtobiomed official said, “Currently, CellShot is actively discussing commercialization with domestic and foreign biotech companies as well as global cell therapy and CDMO companies, and we are confident of securing stable sales and successful market settlement through partnerships with them.” “We have the ability to manufacture consumables that meet the needs of our customers. In addition, through feedback meetings with numerous customers, we provide a process for optimizing consumable combinations and device operating conditions.”
Based on this, Femtobiomed plans to subdivide its lineup from 1 type to 3 types of devices and from 1 type of consumables (cartridges) to 9 types. In addition, a clinically certified device for cell therapy is scheduled to be released in September 2023.
Regarding this, an official said, “Users can freely communicate with AWS-based databases through software installed on the device and a general computer. “We continue to provide updates remotely, such as optimizing operating conditions and improving UI.”
Meanwhile, ‘BIO KOREA 18’, which celebrated its 2023th this year, is hosted by the Korea Health Industry Development Institute and Chungcheongbuk-do. Since 2006, BIO KOREA, which has been striving to promote the global status and continuous growth of the Korean health industry, has been strengthening its position as Korea’s representative bio-health international convention with world-renowned scholars and business experts participating every year. BIO KOREA 2023, together with domestic and foreign companies related to the health industry such as bio, pharmaceuticals, medical devices, cosmetics, and food, as well as companies and institutions of interest such as consulting, academia, and related organizations, offers various programs such as conferences, business partnering, exhibitions, and invest fairs. It goes on.